Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I'm comfortable with the long-term trajectory of the company's new non-addictive opioid and its leading...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
U.S. asks OPEC to increase oil production, Brent slides lower
Global crude fell today after reports that the the U.S. government has asked Saudi Arabia and some other OPEC producers to increase oil production by about 1 million barrels a day. That has sent the international benchmark Brent crude down 0.41% as of 1 p.m.New York...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Book keeping changes: Statoil (STO) changes its name and ticker to Equinor (EQNR)
A change in the name and ticker of portfolio holding Statoil (STO). The explanation offered by the company is that it wanted to remove “oil” from its name to better reflect the company’s increasing emphasis on other forms of energy including wind power. The new name is Equinor (EQNR).
Tech is back with a flood of cash likely to drive prices higher
All is right in tech land again, cash flows say. Last week investors and traders poured $670 million into the Technology Select Sector SPDR ETF (XLK). That’s the most in a year for the second largest technology ETF. Apple (AAPL) is the largest position in the ETF with a 15% weighting.
SolarEdge Technologies beats on earnings and revenue; raises guidance
SolarEdge Technologies (SEDG), a member of my Jubak Picks portfolio, reported first quarter earnings today after the New York markets closed of 87 cents a share, 7 cents a share better than Wall Street projections. Revenue climbed 82.4% year over year (and 10.8% from...
Closing my first two earnings surprise call options with gains of 49% and 70% in less than a month
With the Federal Reserve and Apple’s earnings behind us, this week the market has responded by strongly bidding up the prices of Nvidia and SolarEdge Technologies–and their options–strongly ahead of earnings announcements on May 9 and on May 10. I added call options on these stocks to my Volatility Portfolio on April 17 as the first move in my strategy for profiting from the 2018 earnings boom. My gains: 49% and 70%
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can't find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my Volatility...
